Our top pick for
Building a portfolio
LeMaitre Vascular, Inc is a medical instruments & supplies business based in the US. LeMaitre Vascular shares (LMAT) are listed on the NASDAQ and all prices are listed in US Dollars. LeMaitre Vascular employs 386 staff and has a trailing 12-month revenue of around 0.00.
|52-week range||$23.13 - $54.62|
|50-day moving average||$49.41|
|200-day moving average||$43.00|
|Wall St. target price||$55.40|
|Dividend yield||$0.38 (0.7%)|
|Earnings per share (TTM)||$1.04|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Valuing LeMaitre Vascular stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of LeMaitre Vascular's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
LeMaitre Vascular's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 52x. In other words, LeMaitre Vascular shares trade at around 52x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
LeMaitre Vascular's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 4.005. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into LeMaitre Vascular's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
LeMaitre Vascular's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $36.7 million.
The EBITDA is a measure of a LeMaitre Vascular's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$129.4 million|
|Operating margin TTM||21.89%|
|Gross profit TTM||$84.6 million|
|Return on assets TTM||8.02%|
|Return on equity TTM||13.23%|
|Market capitalisation||$1.1 billion|
TTM: trailing 12 months
There are currently 1.6 million LeMaitre Vascular shares held short by investors – that's known as LeMaitre Vascular's "short interest". This figure is 0.2% up from 1.6 million last month.
There are a few different ways that this level of interest in shorting LeMaitre Vascular shares can be evaluated.
LeMaitre Vascular's "short interest ratio" (SIR) is the quantity of LeMaitre Vascular shares currently shorted divided by the average quantity of LeMaitre Vascular shares traded daily (recently around 126661.11553785). LeMaitre Vascular's SIR currently stands at 12.55. In other words for every 100,000 LeMaitre Vascular shares traded daily on the market, roughly 12550 shares are currently held short.
However LeMaitre Vascular's short interest can also be evaluated against the total number of LeMaitre Vascular shares, or, against the total number of tradable LeMaitre Vascular shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case LeMaitre Vascular's short interest could be expressed as 0.08% of the outstanding shares (for every 100,000 LeMaitre Vascular shares in existence, roughly 80 shares are currently held short) or 0.1073% of the tradable shares (for every 100,000 tradable LeMaitre Vascular shares, roughly 107 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against LeMaitre Vascular.
Find out more about how you can short LeMaitre Vascular stock.
Dividend payout ratio: 29.92% of net profits
Recently LeMaitre Vascular has paid out, on average, around 29.92% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 0.82% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), LeMaitre Vascular shareholders could enjoy a 0.82% return on their shares, in the form of dividend payments. In LeMaitre Vascular's case, that would currently equate to about $0.38 per share.
While LeMaitre Vascular's payout ratio might seem fairly standard, it's worth remembering that LeMaitre Vascular may be investing much of the rest of its net profits in future growth.
LeMaitre Vascular's most recent dividend payout was on 24 March 2021. The latest dividend was paid out to all shareholders who bought their shares by 7 March 2021 (the "ex-dividend date").
Over the last 12 months, LeMaitre Vascular's shares have ranged in value from as little as $23.1282 up to $54.62. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while LeMaitre Vascular's is 1.3337. This would suggest that LeMaitre Vascular's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
LeMaitre Vascular, Inc. designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. It offers angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries or veins; occlusion catheters that temporarily occlude the blood flow; perfusion catheters to perfuse the blood and other fluids into the vasculature; and thrombectomy catheters, which features a silicone balloon for removing thrombi in the venous system. The company also provides carotid shunts that temporarily shunt the blood to the brain during the removal of plaque from the carotid artery in a carotid endarterectomy surgery; powered phlebectomy devices to remove varicose veins; and radiopaque tape, a medical-grade tape applied to the skin that enables interventionists to cross-refer between the inside and the outside of a patient's body, and allows them to locate tributaries or lesions beneath the skin. In addition, it offers remote endarterectomy devices to remove plaque from arteries in the leg; valvulotomes, which cut valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and vascular grafts to bypass or replace diseased arteries. Further, the company provides vascular patches, which are used for closure of vessels after surgical intervention; closure systems to attach vessels to one another with titanium clips instead of sutures; and surgical glue. It markets its products through a direct sales force and distributors.
Everything we know about the Krispy Kreme IPO, plus information on how to buy in.
Everything we know about the Day One Biopharmaceuticals IPO, plus information on how to buy in.
Everything we know about the Enact Holdings IPO, plus information on how to buy in.
Everything we know about the Solid Power IPO, plus information on how to buy in.
Everything we know about the Paymentus Holdings IPO, plus information on how to buy in.
Everything we know about the Qiniu Limited IPO, plus information on how to buy in.
Everything we know about the Qiniu Limited IPO, plus information on how to buy in.
Everything we know about the Ximalaya IPO, plus information on how to buy in.
Everything we know about the Zeta Global Holdings Corp IPO, plus information on how to buy in.
Everything we know about the Paycor HCM IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.